The purpose of this request for applications (RFA) is to facilitate faster translation of important type 1 diabetes (T1D) related research findings into viable immune therapeutic candidates for human testing.
This RFA intends to specifically support late stage preclinical development of promising candidate immune drug and biologic therapies. It is JDRF’s hope that projects successfully completed under this RFA will attract external partners for large scale trials towards regulatory approval of novel therapeutic candidates.
The level of funding for individual projects will vary depending on the scope and overall objectives of a project.
Expressions of interest from strong cross functional teams will be given highest priority.
This RFA is open to academic investigators, biotechnology and pharmaceutical companies, or industry academia partnerships, with preference given to collaborations between academic groups and commercial organisations.
Submission Requirements & Due Dates
- 8 October 2018 – Letter of Intent (LOI) submitted to Sponsor
- 31 December 2018 – full applications submitted for internal review.
- Please email email@example.com if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review